期刊
SUPPORTIVE CARE IN CANCER
卷 19, 期 8, 页码 1079-1095出版社
SPRINGER
DOI: 10.1007/s00520-011-1197-6
关键词
Rash; Xerosis; Paronychia; Pruritus; Radiation dermatitis; Mucositis; EGFR inhibitors; Recommendations
资金
- Bristol-Myers Squibb
- Evolife
- OSI Pharmaceuticals, Inc.
- Amgen, Inc.
- Dermatology Foundation
- Hana Biosciences
- Merck
- Sharp
- Dohme Corporation
Background Epidermal growth factor receptor inhibitors (EGFRI) produce various dermatologic side effects in the majority of patients, and guidelines are crucial for the prevention and treatment of these untoward events. The purpose of this panel was to develop evidence-based recommendations for EGFRI-associated dermatologic toxicities. Methods A multinational, interdisciplinary panel of experts in supportive care in cancer reviewed pertinent studies using established criteria in order to develop first-generation recommendations for EGFRI-associated dermatologic toxicities. Results Prophylactic and reactive recommendations for papulopustular (acneiform) rash, hair changes, radiation dermatitis, pruritus, mucositis, xerosis/fissures, and paronychia are presented, as well as general dermatologic recommendations when possible. Conclusion Prevention and management of EGFRI-related dermatologic toxicities is critical to maintain patients' health-related quality of life and dose intensity of antineoplastic regimens. More rigorous investigation of these toxicities is warranted to improve preventive and treatment strategies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据